A comprehensive review of patients receiving pembrolizumab has found an incidence of abnormal thyroid function tests as high as 15%.
Debra Wood
Advertisement
Articles by Debra Wood
Cabozantinib, an oral multikinase inhibitor, showed promise as second- or third-line therapy in patients with advanced differentiated thyroid cancer (DTC).
Advertisement
Latest Updated Articles
Cabozantinib Shows Promise in Second- and Third-line Differentiated Thyroid CancerPublished: October 21st 2015 | Updated:
Immunotherapy May Lead to Abnormal Thyroid Function in Patients With CancerPublished: October 23rd 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
